None listed
Conditions
Brief summary
This study aims to determine whether patients treated with cefazolin who have incidentally been found to have very low plasma cefazolin concentrations in the course of standard clinical management of invasive bacterial infections have abnormally rapid clearance of this drug. After recovery, these opportunistically-identified patients will be administered a 1g dose of cefazolin and will then have multiple free plasma concentration measurements in the 8 hours post-dose. These data will be used to construct pharmacokinetic curves which will then be compared with known drug pharmacokinetics in normal individuals. Patients will be asked to provide written informed consent prior to enrolment in the study.
Interventions
Administration of a single intravenous dose of 1g of cefazolin over 3-5 minutes
Sponsors
University of Otago
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Abnormally low plasma cefazolin concentration despite standard dosing and/or cefazolin treatment failure not easily explained by an alternative cause Age greater than or equal to 18 years Resolution of index infection Provision of informed consent to participate in the study Able to comply with study procedures
Exclusion criteria
Prior adverse reaction to cefazolin or any of its excipients Poor venous access Most recent haemoglobin concentration below 110g/L for women or 115g/L for men Receipt of cefazolin within the last 7 days
Outcome results
None listed